Publication: Effects of Bardoxolone Methyl on Body Weight, Waist Circumference and Glycemic Control in Obese Patients with T2DM and Stage 4 Chronic Kidney Disease

Bardoxolone methyl treatment resulted in significant weight loss in a generally obese patient population with T2DM and stage 4 CKD, with the magnitude and rate dependent on baseline BMI.

  • Bardoxolone methyl treatment resulted in significant reductions in body weight in a generally overweight patient population with T2DM and stage 4 CKD.
  • The magnitude and rate of weight reductions were more pronounced in patients with higher baseline BMI. The loss in body weight was accompanied by a significant reduction in waist circumference, with declines proportional to both baseline body weight and BMI.
  • In a subset of patients who provided timed urine collections, there was no reduction in 24-hour urinary creatinine excretion, suggesting that bardoxolone methyl does not adversely affect creatinine production and serum creatinine-based eGFR is therefore an appropriate measure of kidney function in response to bardoxolone methyl treatment.